The bioflavonoid galangin blocks aryl hydrocarbon receptor activation and polycyclic aromatic hydrocarbon-induced pre-B cell apoptosis

被引:51
作者
Quadri, SA
Qadri, AN
Hahn, ME
Mann, KK
Sherr, DH
机构
[1] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02118 USA
[2] Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA
关键词
D O I
10.1124/mol.58.3.515
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Bioflavonoids are plant compounds touted for their potential to treat or prevent several diseases including cancers induced by common environmental chemicals. Much of the biologic activity of one such class of pollutants, polycyclic aromatic hydrocarbons (PAH), is mediated by the aryl hydrocarbon receptor/transcription factor (AhR). For example, the AhR regulates PAH immunotoxicity that manifests as pre-B cell apoptosis in models of B cell development. Because bioflavonoids block PAH-induced cell transformation and are structurally similar to AhR ligands, it was postulated that some of them would suppress PAH-induced, AhR-dependent immunotoxicity, possibly through a direct AhR blockade. This hypothesis was tested using a model of B cell development in which pre-B cells are cultured with and are dependent on bone marrow stromal or hepatic parenchymal cell monolayers. Of seven bioflavonoids screened, galangin (3,5,7-trihydroxyflavone) blocked PAH-induced but not C-2-ceramide- or H2O2-induced pre-B cell apoptosis. Because galangin blocked AhR-dependent reporter gene expression, AhR complex-DNA binding, and AhR nuclear translocation, inhibition of a relatively early step in AhR signaling was implicated. This hypothesis was supported by the ability of galangin to bind the AhR and stabilize AhR-90-kDa heat shock protein complexes in the presence of AhR agonists. These studies demonstrate the utility of pre-B cell culture systems in identifying compounds capable of blocking PAH immunotoxicity, define at least one mechanism of galangin activity (i.e., repression of AhR activation), and motivate the use of this and similar dietary bioflavonoids as relatively nontoxic inhibitors of AhR agonist activity and as pharmacologic agents with which to dissect AhR signaling pathways.
引用
收藏
页码:515 / 525
页数:11
相关论文
共 41 条
[1]   Skin cancer chemopreventive effects of a flavonoid antioxidant silymarin are mediated via impairment of receptor tyrosine kinase signaling and perturbation in cell cycle progression [J].
Ahmad, N ;
Gali, H ;
Javed, S ;
Agarwal, R .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (02) :294-301
[2]  
BLANK JA, 1987, MOL PHARMACOL, V32, P168
[3]  
Carver LA, 1997, J BIOL CHEM, V272, P11452
[4]   Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells [J].
Chen, I ;
Safe, S ;
Bjeldanes, L .
BIOCHEMICAL PHARMACOLOGY, 1996, 51 (08) :1069-1076
[5]   Dexamethasone-induced thymocyte apoptosis: Apoptotic signal involves the sequential activation of phosphoinositide-specific phospholipase C, acidic sphingomyelinase, and caspases [J].
Cifone, MG ;
Migliorati, G ;
Parroni, R ;
Marchetti, C ;
Millimaggi, D ;
Santoni, A ;
Riccardi, C .
BLOOD, 1999, 93 (07) :2282-2296
[6]   Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially [J].
Ciolino, HP ;
Daschner, PJ ;
Yeh, GC .
BIOCHEMICAL JOURNAL, 1999, 340 :715-722
[7]   The flavonoid galangin is an inhibitor of CYP1A1 activity and an agonist/antagonist of the aryl hydrocarbon receptor [J].
Ciolino, HP ;
Yeh, GC .
BRITISH JOURNAL OF CANCER, 1999, 79 (9-10) :1340-1346
[8]  
Ciolino HP, 1998, CANCER RES, V58, P5707
[9]   INDUCIBLE, RECEPTOR-DEPENDENT PROTEIN-DNA INTERACTIONS AT A DIOXIN-RESPONSIVE TRANSCRIPTIONAL ENHANCER [J].
DENISON, MS ;
FISHER, JM ;
WHITLOCK, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (08) :2528-2532
[10]   Hydrogen peroxide-induced apoptosis is CD95-independent, requires the release of mitochondria-derived reactive oxygen species and the activation of NF-κB [J].
Dumont, A ;
Hehner, SP ;
Hofmann, TG ;
Ueffing, M ;
Dröge, W ;
Schmitz, ML .
ONCOGENE, 1999, 18 (03) :747-757